The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status
- PMID: 25602796
- PMCID: PMC4428379
- DOI: 10.1097/PAS.0000000000000381
The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status
Abstract
Diagnostic interpretation of a cervical biopsy is a key element in the decision to treat or not to treat a woman with an abnormal screening test. This study assesses the variability of these diagnostic interpretations on a population basis using the New Mexico HPV Pap Registry database. An experienced panel of gynecologic pathologists reviewed a stratified random sample of 6272 biopsies, which was then extrapolated to the entire population of 21,297 biopsies read by the community pathologists. Diagnoses by the community and panel pathologists were compared, and paired diagnoses were correlated with positivity for human papillomavirus 16 (HPV16) and any high-risk HPV as objective measures of progressive potential. Panel agreement with the community diagnosis was 38.2% for cervical intraepithelial neoplasia grade 1 (CIN1), 38.0% for CIN grade 2 (CIN2), 68.0% for CIN grade 3 (CIN3), and 70.6% for cancer. The κ value was 0.46 overall but higher for dichotomous categorization based on CIN2 or CIN3 cutoff points (0.68 and 0.67, respectively). On a population basis, there were fewer CIN1 and more negative diagnoses in the panel review but similar proportions of CIN2 and CIN3. HPV16 and high-risk HPV positivity increased with disease severity, but panel review did not improve the correlation of higher-grade disease with these objective measures. In this population-based study of the variability in cervical diagnoses, we noted significant variability in the community and panel diagnoses, especially for CIN2, the threshold for excisional treatment. New biomarkers are needed to more accurately stratify precursor lesions according to their malignant potential.
Conflict of interest statement
Conflicts of Interest and Source of Funding: Supported by the National Cancer Institute (NCI) under Award Number R01CA134779 and the National Institute of Allergy And Infectious Diseases (NIAID) of the National Institutes of Health under Award Number U19AI084081 to C.M.W. Roche Molecular Systems Inc. provided HPV Linear Array Genotyping test reagents and equipment to automate HPV genotyping assays through the University of New Mexico. M.H.S. has served as a consultant and/or expert pathologist in HPV-related vaccine and/or diagnostic clinical trials for Merck, Roche, Hologic/Gen-Probe, BD, Qiagen, Cepheid, and Inovio. B.M.R. has served as a consultant and/or expert pathologist in HPV-related vaccine and/or diagnostic clinical trials for Merck. J.C. has received research funding and reagents from Qiagen, Roche, GenProb/Hologic, Abbott, BD, Cepheid, Genera, and Trovagene, and has been personally compensated for Advisory Boards or Speakers Bureau activities from Gen-Probe/Hologic, Abbott, BD, Merck, and Cepheid. C.W. has received equipment and reagents for HPV genotyping from Roche Molecular Systems and contracts from Merck and GSK for HPV vaccine trials through her institution, the University of New Mexico. For the remaining authors none were declared.
References
-
- Cai B, Ronnett BM, Stoler M, et al. Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists. Am J Surg Pathol. 2007;31:1854–1860. - PubMed
-
- de Vet HC, Knipschild PG, Schouten HJ, et al. Interobserver variation in histopathological grading of cervical dysplasia. J Clin Epidemiol. 1990;43:1395–1398. - PubMed
-
- de Vet HC, Knipschild PG, Schouten HJ, et al. Sources of interobserver variation in histopathological grading of cervical dysplasia. J Clin Epidemiol. 1992;45:785–790. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
